by AdoloreJTC24 | Jun 10, 2024 | Press Releases
Live video webcast on Monday, June 17th at 10:00 AM ET DELRAY BEACH, FL / June 10, 2024 / Adolore BioTherapeutics (“Adolore” or the “Company”), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for...
by AdoloreJTC24 | May 21, 2024 | Press Releases
Development program for the treatment of osteoarthritis (OA) chronic knee pain is fully funded through the first-in-human clinical study by a UG3/UH3 grant awarded by NIH/NINDS HEAL programOngoing progress with IND-enabling studies of ADLR-1001 gene therapy for the...
by AdoloreJTC24 | May 16, 2024 | Press Releases
Findings highlight the advantages of Adolore’s approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediate profound analgesia with the potential to address the great unmet need for...
by AdoloreJTC24 | Mar 4, 2024 | Press Releases
Patent and CA8* gene therapy technology licensed by Adolore BioTherapeutics from the University of MiamiCompany advancing development of rdHSV-CA8* gene therapy for the treatment of chronic osteoarthritis (OA) knee pain toward an INDDELRAY BEACH, FL / March 4, 2024 /...
by AdoloreJTC24 | Jan 30, 2024 | Press Releases
DELRAY BEACH, FL / January 30, 2024 / Adolore BioTherapeutics (“Adolore” or the “Company”), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced that Roy C. Levitt, MD,...
by AdoloreJTC24 | Dec 5, 2023 | Press Releases
Innovative rdHSV-based CA8* gene therapy demonstrates preclinical proof-of-concept as a disease-modifying long-acting local analgesic to replace opioids in chronic osteoarthritis (OA) knee pain managementDELRAY BEACH, FL / December 5, 2023 / Adolore BioTherapeutics...
